1 Surging Stock with Solid Fundamentals and 2 That Underwhelm
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
But not every company with momentum is a long-term winner, and plenty of investors have lost money betting on short-term fads. Keeping that in mind, here is one stock with lasting competitive advantages and two not so much.
Two Stocks to Sell:
Caesars Entertainment (CZR)
One-Month Return: -0.6%
Formerly Eldorado Resorts, Caesars Entertainment (NASDAQ:CZR) is a global gaming and hospitality company operating numerous casinos, hotels, and resort properties.
Why Do We Think CZR Will Underperform?
- Annual sales growth of 10% over the last five years lagged behind its consumer discretionary peers as its large revenue base made it difficult to generate incremental demand
- Eroding returns on capital from an already low base indicate that management’s recent investments are destroying value
- High net-debt-to-EBITDA ratio of 7× could force the company to raise capital on unfavorable terms if market conditions deteriorate
Caesars Entertainment’s stock price of $29.58 implies a valuation ratio of 88.6x forward P/E. Dive into our free research report to see why there are better opportunities than CZR.
West Pharmaceutical Services (WST)
One-Month Return: +2.6%
Founded in 1923 and serving as a critical link in the pharmaceutical supply chain, West Pharmaceutical Services (NYSE:WST) manufactures specialized packaging, containment systems, and delivery devices for injectable drugs and healthcare products.
Why Does WST Worry Us?
- Sales trends were unexciting over the last five years as its 5.7% annual growth was below the typical healthcare company
- Day-to-day expenses have swelled relative to revenue over the last five years as its adjusted operating margin fell by 5.3 percentage points
- Shrinking returns on capital suggest that increasing competition is eating into the company’s profitability
At $362.14 per share, West Pharmaceutical Services trades at 39.5x forward P/E. Check out our free in-depth research report to learn more about why WST doesn’t pass our bar.
One Stock to Watch:
Darling Ingredients (DAR)
One-Month Return: -0.9%
Turning what others consider waste into valuable resources, Darling Ingredients (NYSE:DAR) collects and transforms animal by-products, used cooking oil, and other bio-nutrients into valuable ingredients for food, feed, fuel, and industrial applications.
Why Do We Like DAR?
- Operating margin increased by 9.5 percentage points over the last year as it refined its cost structure
- Free cash flow margin expanded by 3.8 percentage points over the last year, providing additional flexibility for investments and share buybacks/dividends
- Industry-leading 16.1% return on capital demonstrates management’s skill in finding high-return investments
Darling Ingredients is trading at $65.15 per share, or 10x forward P/E. Is now a good time to buy? See for yourself in our comprehensive research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.